Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment Tibor Stark, Martina Di Bartolomeo, Roberta Di Marco, Eva Drazanova, Chiara Bianca Maria Platania, Fabio Arturo Iannotti, Jana Ruda-Kucerova, Claudio D'Addario, Lucie Kratka, Vladimir Pekarik, Fabiana Piscitelli, Zuzana Babinska, Julia Fedotova, Giovanni Giurdanella, Salvatore Salomone, Alexandra Sulcova, Claudio Bucolo, Carsten T.Wotjak, Zenon Starcuk Jr, Filippo Drago, Raphael Mechoulam, Vincenzo Di Marzo, Vincenzo Micale Biochemical Pharmacology, April 2020, 1-12. doi : 10.1016/j.bcp.2020.114004 Un excellent article international (République Tchèque, Allemagne, Italy, Russie, Israel, Canada), avec la plus grande plume de la recherche sur les cannabinoïdes (Mechoulam, Di Marzo...) qui [...]
Lire la suiteIn Search of Preventative Strategies: Novel Anti- Inflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues Bo Wang, Anna Kovalchuk, Dongping Li, Yaroslav Ilnytskyy, Igor Kovalchuk and Olga Kovalchuk Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 19 April 2020 doi : 10.20944/preprints202004.0315.v1 Abstract : With the rapidly growing pandemic of COVID-19 caused by the new and challenging to treat zoonotic SARS-CoV2 coronavirus, there is an urgent need for new therapies and prevention strategies that can help curtail disease spread and reduce mortality. Inhibition of viral entry and thereby spread constitute plausible therapeutic avenues. Similar to other respiratory pathogens, SARS-CoV2 is transmitted [...]
Lire la suiteCannabinoids and the Coronavirus Kevin P. Hill Cannabis and Cannabinoid Research, 2020, Volume 5, Number 2, Doi : 10.1089/can.2020.0035 Introduction These are uncertain times as we attempt to manage our lives during the Coronavirus Covid-19 pandemic. It is not surprising, as possible treatments for Covid-19 are discussed, that people wonder about a role for cannabinoids, another topic associated with a lack of clarity about their therapeutic efficacy. Patients commonly ask clinicians about the benefits and risks of cannabinoids and now patients have begun to ask about cannabinoids as they relate to Covid-19. This interest creates an opportunity to strengthen the therapeutic alliance between patients and [...]
Lire la suiteDissiper la fumée entourant le cannabis : Effets du cannabis pendant la grossesse – version actualisée Amy J. Porath, Ph.D., Directrice, Recherche, CCDUS Sarah Konefal, Ph.D., Analyste, Recherche et politiques, CCDUS Pam Kent, Ph.D., Directrice associée, Recherche, CCDUS Centre Canadien sur les dépendances et l'usage de substances, 2018 Le présent rapport est le deuxième d’une série sur les effets du cannabis sur divers aspects du fonctionnement et du développement de la personne. Révision d’un rapport précédent, il aborde les effets sur l’enfant et les jeunes adultes de la consommation de cannabis pendant la grossesse et fait état des nouvelles recherches qui valident et approfondissent nos connaissances sur [...]
Lire la suiteRationale for cannabis-based interventions in the opioid overdose crisis Philippe Lucas Harm Reduction Journal, 2017, 14, 58 Doi : 10.1186/s12954-017-0183-9 Abstract Background : North America is currently in the grips of a crisis rooted in the use of licit and illicit opioid-based analgesics. Drug overdose is the leading cause of accidental death in Canada and the US, and the growing toll of opioid-related morbidity and mortality requires a diversity of novel therapeutic and harm reduction-based interventions. Research suggests that increasing adult access to both medical and recreational cannabis has significant positive impacts on public health and safety as a result of substitution effect. Observational and [...]
Lire la suitePotential combinations of endocannabinoid/endocannabinoid-like compounds and antibiotics against methicillin-resistant Staphylococcus aureus Mark Feldman, Reem Smoum, Raphael Mechoulam, Doron Steinberg PLoS One, April 15, 2020, 1-13. Doi : 10.1371/journal.pone.0231583 Abstract Infections caused by antibiotic-resistant strains of Staphylococcus aureus have reached epidemic proportions globally. Our previous study showed antimicrobial effects of anandamide (AEA) and arachidonoyl serine (AraS) against methicillin (MET)-resistant S. aureus (MRSA) strains, proposing the therapeutic potential of these endocannabinoid/endocannabinoid-like (EC/EC-like) agents for the treatment of MRSA. Here, we investigated the potential synergism of combinations of AEA and AraS with different types of antibiotics against MRSA grown under planktonic growth or biofilm formation. The most effective [...]
Lire la suiteCannabis Use Patterns and Motives: A Comparison of Younger, Middle-Aged, and Older Medical Cannabis Dispensary Patients Nancy A. Haug, Claudia B. Padula, James E. Sottile, Ryan Vandrey, Adrienne J. Heinz, and Marcel O. Bonn-Miller Addictive Behaviors, 2017, 72, 14-20. Doi : 10.1016/j.addbeh.2017.03.006 Abstract Introduction : Medical cannabis is increasingly being used for a variety of health conditions as more states implement legislation permitting medical use of cannabis. Little is known about medical cannabis use patterns and motives among adults across the lifespan. Methods : The present study examined data collected at a medical cannabis dispensary in San Francisco, California. Participants included 217 medical cannabis patients who [...]
Lire la suiteUn hôpital commence à traiter les patients du COVID-19 avec le cannabis, Times of Israel . com, 2020
Un hôpital commence à traiter les patients du COVID-19 avec le cannabis https://fr.timesofisrael.com/liveblog_entry/un-hopital-commence-a-traiter-les-patients-du-covid-19-avec-le-cannabis/ L’hôpital Ichilov a commencé à administrer du cannabis médicinal aux patients atteints du coronavirus en état modéré dans le cadre d’un traitement expérimental, a rapporté la Douzième chaîne. Les docteurs cherchent à utiliser les propriétés antivirales du cannabis pour ralentir la propagation du virus, a annoncé l’hôpital.
Lire la suitePrevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids. A Systematic Review and Meta-analysis Anees Bahji, MD; Callum Stephenson; Richard Tyo, BSocSc, RP; Emily R. Hawken, MSc, PhD; Dallas P. Seitz, MD, PhD JAMA Network Open, 2020, 3, (4), e202370. doi : 10.1001/jamanetworkopen.2020.2370 Abstract IMPORTANCE : Cannabis withdrawal syndrome (CWS)—a diagnostic indicator of cannabis use disorder—commonly occurs on cessation of heavy and prolonged cannabis use. To date, the prevalence of CWS syndrome has not been well described, nor have the factors potentially associated with CWS. OBJECTIVES : To estimate the prevalence of CWS among individuals with regular or dependent use of [...]
Lire la suiteLa classification des substances psychoactives. Lorsque la science n’est pas écoutée Commission Globale de Politique en Matière de Drogues Rapport 2019 Sommaire Avant-propos................................................................................................................................ 3 Résumé......................................................................................................................................... 4 Classification des drogues : science ou idéologie?....................................................................... 7 Le système international de classification.................................................................................. 13 Histoire du régime mondial de contrôle des drogues................................................................. 13 Les incohérences corrompent le système actuel......................................................................... 16 Défaut d’équilibre : l’accès aux médicaments sous contrôle....................................................... 19 Recommandation......................................................................................................................... 21 Les enseignements des marchés (semi-)légaux.......................................................................... 25 Les plantes psychoactives non-classées...................................................................................... 25 La régulation légale du cannabis................................................................................................. 26 Les nouvelles substances psychoactives...................................................................................... 27 Recommandation......................................................................................................................... 29 Difficultés et options de réforme................................................................................................. 31 Améliorer le système actuel......................................................................................................... 31 Une échelle rationnelle des risques............................................................................................. 33 Redonner de la flexibilité nationale pour la régulation légale.................................................... 35 Recommandation........................................................................................................................ 37 Observations finales.................................................................................................................... [...]
Lire la suite